Paid Advertisement
Transthyretin cardiac amyloidosis (or ATTR-CM) is a serious, underrecognized, and underdiagnosed cause of heart failure. Through patient case studies and expert discussion, this program will explore identification and diagnosis of ATTR-CM and management with an oral medication option. Clinical data for this agent will be presented, including long-term extension data and recently published findings from a real-world study.
This event is not part of the official Scientific Sessions Conference 2024 as planned by the American Heart Association Committee on Scientific Sessions Programming.